Quotes 5-day view Delayed Nyse
11/22/2021
11/23/2021
11/24/2021
11/26/2021
11/29/2021
Date
181.76(c)
179.62(c)
176.95(c)
183.09(c)
183.43 Last
922 815
712 322
1 015 198
633 271
9 965 Volume
-3.74% -1.18% -1.49% +3.47% +0.19% Change
Estimated financial data (e) (USD)
Sales 2021
4 922 M - -
Net income 2021
951 M - -
Net Debt 2021
4 157 M - -
P/E ratio 2021
22,3x
Yield 2021
0,15%
Sales 2022
4 258 M - -
Net income 2022
631 M - -
Net Debt 2022
3 499 M - -
P/E ratio 2022
36,5x
Yield 2022
0,15%
Capitalization
23 106 M 23 106 M -
EV / Sales 2021
5,54x
EV / Sales 2022
6,25x
Nbr of Employees
14 000
Free-Float
99,8%
PerkinElmer, Inc. is a provider of products, services and solutions for the diagnostics, life sciences and applied markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides products and services targeted towards the life sciences and applied markets. The Diagnostics segment develops diagnostics, tools and applications...
Ratings of PerkinElmer, Inc.
All news about PERKINELMER, INC.
11/22 PerkinElmer, Inc. Launches Cloud Based Solution to Enable Remote Lab Management CI
11/16 PerkinElmer to Present at Evercore ISI HealthCONx Conference 2021 BU
11/09 PERKINELMER INC Management's Discussion and Analysis of Financial Condition and Result.. AQ
11/05 PerkinElmer to Present at 2021 Stifel Healthcare Conference BU
11/04 BioLegend, Inc. and subsidiaries Index to financial statements - Form 8-K/A PU
11/04 PERKINELMER INC Completion of Acquisition or Disposition of Assets, Financial Statemen.. AQ
11/04 PerkinElmer, Inc. agreed to acquire 27.5% stake in YuanDian Biolabs Co., LTD for $5.5 m.. CI
11/03 Stifel Adjusts Price Target on PerkinElmer to $187 From $175, Maintains Buy Rating MT
11/03 JPMorgan Adjusts Price Target on PerkinElmer to $180 From $168, Maintains Neutral Ratin.. MT
11/03 Wells Fargo Adjusts Price Target on PerkinElmer to $200 from $190, Keeps Overweight Rat.. MT
11/03 Baird Adjusts PerkinElmer's Price Target to $206 From $183, Keeps Outperform Rating MT
11/02 PerkinElmer Fiscal Q3 Adjusted EPS, Revenue Advance; Company Boosts FY Outlook MT
11/02 PERKINELMER : Q3 Earnings SnapshotAQ
11/02 PerkinElmer Announces Financial Results for the Third Quarter of 2021 - Form 8-K PU
11/02 PERKINELMER INC : Results of Operations and Financial Condition (form 8-K)AQ
News in other languages on PERKINELMER, INC.
Analyst Recommendations on PERKINELMER, INC.
PERKINELMER, INC. - 05/17
Technically solid
BUY
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends PERKINELMER, INC.
Short Term Mid-Term Long Term Trends Neutral Bullish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
183,09 $
Average target price
185,27 $
Spread / Average Target
1,19%
Please enable JavaScript in your browser's settings to use dynamic charts.
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
